Company intelligence / Profile preview
Relay Therapeutics
Cambridge, Massachusetts, United Statesrelaytx.com ↗
- Ownership
- Public · RLAY
- Employees
- ~500
- Development stage
- Phase 2
01
Overview
Advancing multiple programs including RLY-2608 (first-in-class mutant-selective PI3Kα inhibitor) which has shown lesion regressions in experimental models of PIK3CA-related vascular malformations, and other candidates in various clinical stages[4]
- Therapeutic areas
- Rare DiseasesOncologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Elevar Therapeutics (global outlicense for Lirafugratinib/RLY-4008)[4]
04
Financials
- Market cap
- $4.1B
- Total revenue
- $350K
- Enterprise value
- $3.3B
Beyond the preview
Go deeper on Relay Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Relay Therapeutics.